UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


FORM 8-K


CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): August 11, 2017


KINDRED BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)



 
 
 
 
 
Delaware
 
001-36225
 
46-1160142
(State or other jurisdiction of
incorporation or organization)
 
(Commission
File Number)
 
(I.R.S. Employer
Identification No.)
1555 Bayshore Highway, Suite 200, Burlingame, California 94010
(Address of principal executive offices) (Zip Code)

(650) 701-7901
(Registrant’s telephone number, include area code)
N/A
(Former Name or Former Address, if Changed Since Last Report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
 
 
    Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x






Item 8.01      Other Events.
On August 11, 2017, Kindred Biosciences, Inc. (the “Company”) completed the closing of the exercise of the underwriters' option to purchase an additional 314,000 shares of common stock at the public offering price of $7.50 per share as part of the firm commitment underwritten offering that initially closed on July 17, 2017, resulting in additional gross proceeds to the Company of approximately $2.3 million. After giving effect to this exercise of the over-allotment option, the total number of shares sold by Company in the public offering increased to 3,314,000 shares and gross proceeds increased to approximately $24.8 million.
Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc. (NYSE MKT:LTS), acted as sole book-running manager and Aegis Capital Corp. acted as the lead manager. The shares were offered by the Company pursuant to an automatically effective shelf registration statement that was previously filed with the Securities and Exchange Commission (“SEC”). A prospectus supplement relating to, and describing the terms of, the offering was previously filed with the SEC and is available on the SEC’s web site at www.sec.gov. Copies of the prospectus supplement and the accompanying prospectus relating to the offering can be obtained from Ladenburg Thalmann, 277 Park Avenue, 26th Floor, New York, NY 10172 or by email at prospectus@ladenburg.com.
The information furnished under this Item 8.01 shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liability of such section, nor shall such information be deemed to be incorporated by reference in any subsequent filing by the Company under the Securities Act of 1933 or the Exchange Act, regardless of the general incorporation language of such filing, except as specifically stated in such filing.








SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 14, 2017
Kindred Biosciences, Inc.
 
 
By:
/s/ Richard Chin
 
   Richard Chin, M.D.
 
   President and Chief Executive Officer
 
 





Kindred Biosciences (NASDAQ:KIN)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Kindred Biosciences Charts.
Kindred Biosciences (NASDAQ:KIN)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Kindred Biosciences Charts.